"U.S. cancer survivors face significant economic burdens due to growing medical costs, missed work, and reduced productivity, according to a study by the Centers for Disease Control and Prevention in today’s Morbidity and Mortality Weekly"...
Mechanism of Action
In humans, uric acid is the final step in the catabolic pathway of purines. Rasburicase catalyzes enzymatic oxidation of poorly soluble uric acid into an inactive and more soluble metabolite (allantoin).
The measurement of plasma uric acid was used to evaluate the effectiveness of rasburicase in clinical studies. Following administration of either 0.15 or 0.20 mg/kg rasburicase daily for up to 5 days, plasma uric acid levels decreased within 4 hours and were maintained below 7.5 mg/dL in 98% of adult and 90% of pediatric patients for at least 7 days. There was no evidence of a dose response effect on uric acid control for doses between 0.15 and 0.20 mg/kg rasburicase.
The pharmacokinetics of rasburicase were evaluated in both pediatric and adult patients with leukemia, lymphoma or other hematological malignancies. Rasburicase exposure, as measured by AUC0-24 hr and Cmax, tended to increase with a dose range from 0.15 to 0.2 mg/kg. The mean terminal half-life was similar between pediatric and adult patients and ranged from 15.7 to 22.5 hours. The mean volume of distribution of rasburicase ranged from 110 to 127 mL/kg in pediatric patients and from 75.8 to 138 mL/kg in adult patients, respectively. Minimal accumulation of rasburicase ( < 1.3 fold) was observed between days 1 and 5 of dosing. In adults, age, gender, baseline liver enzymes and creatinine clearance did not impact the pharmacokinetics of rasburicase. A cross-study comparison revealed that after administration of rasburicase at 0.15 or 0.20 mg/kg, the geometric mean values of body-weight normalized clearance were approximately 40% lower in Japanese (n=20) than that in Caucasians (n=22).
Reproductive and Developmental Toxicology
Pregnant rabbits dosed daily with 10 to 100 times the human dose of rasburicase during the period of organogenesis (gestation day 6 – 19) exhibited teratogenic effects, clinical signs of maternal toxicity including weight loss and mortality, decreases in uterine weights and viable fetuses, and increased fetal resorptions, post-implantation losses and abortions. Teratogenic effects included multiple heart and great vessel malformations at all dose levels. Multiple heart and great vessel malformations were also observed in offspring of pregnant rats treated with approximately 250 times the recommended human dose of rasburicase. There are no data available regarding the level of rasburicase exposure in the offspring.
Elitek (rasburicase) was administered in three studies to 265 patients with acute leukemia or non-Hodgkin's lymphoma. These clinical studies were largely limited to pediatric patients (246 of 265). Elitek (rasburicase) was administered as a 30-minute infusion once (n=251) or twice (n=14) daily at a dose of 0.15 or 0.2 mg/kg/dose (total daily dose 0.2-0.4 mg/kg/day). Elitek (rasburicase) was administered prior to and concurrent with anti-tumor therapy, which consisted of either systemic chemotherapy (n=196) or steroids (n=69).
Study 1 was a randomized, open-label, controlled study conducted at six institutions, in which 52 pediatric patients were randomized to receive either Elitek (rasburicase) (n=27) or allopurinol (n=25). The dose of allopurinol varied according to local institutional practice. Elitek (rasburicase) was administered as an intravenous infusion over 30 minutes once (n=26) or twice (n=1) daily at a dose of 0.2 mg/kg/dose (total daily dose 0.2-0.4 mg/kg/day). Initiation of dosing was permitted at any time between 4 to 48 hours before the start of anti-tumor therapy and could be continued for 5 to 7 days after initiation of anti-tumor therapy. Patients were stratified at randomization on the basis of underlying malignant disease (leukemia or lymphoma) and baseline serum or plasma uric acid levels ( < 8 mg/dL and ≥ 8 mg/dL). The primary study objective was to demonstrate a greater reduction in uric acid concentration over 96 hours (AUC0-96 hr) in the Elitek (rasburicase) group as compared to the allopurinol group. Uric acid AUC0-96 hr was defined as the area under the curve for plasma uric acid levels (mg hr/dL), measured from the last value prior to the first dose of Elitek (rasburicase) until 96 hours after that first dose. Plasma uric acid levels were used for all uric acid AUC0-96 hr calculations [see WARNINGS AND PRECAUTIONS].
The demographics of the two study arms (Elitek (rasburicase) vs. allopurinol) were as follows: age < 13 years (82% vs. 76%), males (59% vs. 72%), Caucasian (59% vs. 72%), ECOG performance status 0 (89% vs. 84%), and leukemia (74% vs. 76%). The median interval, in hours, between initiation of Elitek (rasburicase) and of anti-tumor treatment was 20 hours, with a range of 70 hours before to 10 hours after the initiation of anti-tumor treatment (n=24, data not reported for 3 patients).
The uric acid AUC0-96 hr was significantly lower in the Elitek (rasburicase) group (128 ± s.e. 14 mg hr/dL) as compared to the allopurinol group (328 ± s.e. 26 mg hr/dL). All but one patient in the Elitek (rasburicase) arm had reduction and maintenance of uric acid levels to within or below the normal range during the treatment. The incidence of renal dysfunction was similar in the two study arms; one patient in the allopurinol arm developed acute renal failure.
Study 2 was a multi-institutional, single-arm study conducted in 89 pediatric and 18 adult patients with hematologic malignancies. Patients received Elitek (rasburicase) at a dose of 0.15 mg/kg/day. The primary efficacy objective was determination of the proportion of patients with maintained plasma uric acid concentration at 48 hours where maintenance of uric acid concentration was defined as: 1) achievement of uric acid concentration ≤ 6.5 mg/dL (patients < 13 years) or ≤ 7.5 mg/dL (patients ≥ 13 years) within a designated time point (48 hours) from initiation of Elitek (rasburicase) and maintained until 24 hours after the last administration of study drug; and 2) control of uric acid level without the need for allopurinol or other agents.
The study population demographics were: age < 13 years (76%), males (61%), Caucasian (91%), ECOG performance status=0 (92%), and leukemia (89%).
The proportion of patients with maintenance of uric acid concentration at 48 hours in Study 2 was 99% (106/107).
Study 3 was a multi-institutional, single-arm study conducted in 130 pediatric patients and 1 adult patient with hematologic malignancies. Patients received Elitek (rasburicase) at either a dose of 0.15 mg/kg/day (n=12) or 0.2 mg/kg/day (n=119). The primary efficacy objective was determination of the proportion of patients with maintained plasma uric acid concentration at 48 hours as defined for Study 2 above.
The study population demographics were: age < 13 years (76%), Caucasian (83%), males (67%), ECOG=0 (67%), and leukemia (88%).
The proportion of patients with maintenance of uric acid concentration at 48 hours in Study 3 was 92% in the 0.15 mg/kg group (n=12) and 95% in the 0.2 mg/kg group (n=119).
Pooled Analyses of Studies 1, 2, and 3
Data from the 3 studies (n=265) were pooled and analyzed according to the plasma uric acid levels over time. The pre-treatment plasma uric acid concentration was ≥ 8 mg/dL in 61 patients and was < 8 mg/dL in 200 patients. The median uric acid concentration at baseline, at 4 hours following the first dose of Elitek (rasburicase) , and the per patient fall in plasma uric acid concentration from baseline to 4 hours were calculated in those patients with both pre-treatment and 4-hour post-treatment values. Among patients with pre-treatment uric acid ≥ 8 mg/dL [baseline median 10.6 mg/dL (range 8.1 – 36.4)], the median per-patient change in plasma uric acid concentration by 4 hours after the first dose was a decrease of 9.1 mg/dL (0.3 - 19.3 mg/dL). Among the patients with a pre-treatment plasma uric acid level < 8 mg/dL [baseline median 4.6 mg/dL (range 0.2 - 7.9 mg/dL)], the median per-patient change in plasma uric acid concentration by 4 hours after the first dose was a decrease of 4.1 mg/dL (0.1 - 7.6 mg/dL).
Figure 1. Box and Whisker Plot of Uric Acid Concentration
at designated time blocks. ELITEK (rasburicase) administration began immediately after baseline.
Figure 1 is a box and whisker plot of plasma uric acid levels inclusive of 261 of the 265 Elitek (rasburicase) treated patients from Studies 1, 2, and 3. Of the 261 evaluable patients, plasma uric acid concentration was maintained [see Study 2 for the definition of uric acid concentration maintenance], by 4 hours for 92% of patients (240/261), by 24 hours for 93% of patients (245/261), by 48 hours for 97% of patients (254/261), by 72 hours for 99% of patients (260/261), and by 96 hours for 100% of patients (261/261). Of the subset of 61 patients whose plasma uric acid level was elevated at baseline ( ≥ 8 mg/dL), plasma uric acid concentration was maintained by 4 hours for 72% of patients (44/61), by 24 hours for 80% of patients (49/61), by 48 hours for 92% of patients (56/61), by 72 hours for 98% of patients (60/61), and by 96 hours for 100% (61/61).
Studies in Adults
A total of 342 adults with either leukemia, lymphoma, or other hematologic malignancy received Elitek (rasburicase) in five studies (one randomized study, Study 4, and four uncontrolled studies). Across the five studies, Elitek (rasburicase) was administered at a dose of 0.15 mg/kg/day (n=38) or 0.2 mg/kg/day (n=304).
Study 4 was a randomized (1:1:1), multi-center, open-label study conducted in patients with leukemia, lymphoma, and solid tumor malignancies at risk for hyperuricemia and TLS. A total of 275 adult patients received at least one dose of study drug. The median age was 56 years, 62% were males, 80% were Caucasian, 66% had leukemia, 29% had lymphoma, 18% were hyperuricemic (uric acid ≥ 7.5mg/dL) at study entry. Patients in Arm A received Elitek (rasburicase) for 5 days (n=92). Patients in Arm B received Elitek (rasburicase) from day 1 through day 3 followed by oral allopurinol from day 3 through day 5 (overlap on day 3: Elitek (rasburicase) and allopurinol administered approximately 12 hours apart) (n=92). Patients in Arm C received oral allopurinol for 5 days (n=91). Elitek (rasburicase) was administered at the dose of 0.2 mg/kg/day as a 30-minute infusion once daily. Allopurinol was administered orally at the dose of 300 mg once a day. Patients were eligible for the study if they were either at high risk, or potential risk for TLS. The major endpoint of this study was the uric acid response rate defined as the proportion of patients with plasma uric acid levels ≤ 7.5 mg/dL from day 3 to day 7, after initiation of antihyperuricemic treatment.
Table 2 presents the response rates in the three treatment arms. The response rate in arm A was significantly greater than in arm C (p=0.0009). The response rate was higher for arm B compared to arm C; this difference was not statistically significant.
Table 2 – Summary of Response Rates
| Arm A Elitek
| Arm BElitek /Allopurinol
| Arm CAllopurinol
|Response Rate % (95% CI)||87% (80%, 94%)||78% (70%, 87%)||66% (56%, 76%)|
|Non-Response Rate %||13%||22%||34%|
|Failed to control uric acid||0||0||11%|
|Hyperuricemic treatment extended beyond 5 days||0||6.5%||4.4%|
|Missing uric acid samples||13%||15%||19%|
There were no patients with documented failure to control uric acid in arms A or B. In arm C, 34% of patients did not have a uric acid response; 11% due to failure to control uric acid and 4.4% due to the need for extended antihyperuricemic treatment.
Box and whisker plots of uric acid over time for the patient population (Figure 2) show that in the two arms containing Elitek (rasburicase) , uric acid levels were ≤ 2 mg/dL in 96% of patients at 4 hours of the day 1 dose.
Figure 2 – Uric acid concentration over time – Patient population
Tumor lysis syndrome (TLS)
Clinical TLS was defined by changes in at least two or more laboratory parameters for hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia and at least one of the following events occurring within 7 days of treatment: renal failure/injury, need for renal dialysis, and/or serum creatinine increase > 1.5 ULN, arrhythmia or seizure. Clinical TLS occurred in 3% of Elitek (rasburicase) -treated patients, 3% of Elitek (rasburicase) /allopurinol-treated patients, and 4% of allopurinol-treated patients.
Last reviewed on RxList: 11/2/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Elitek Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.